Bristol Cements Lead In Immunotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval for Opdivo and Yervoy in combination and Opdivo as monotherapy for the treatment of all metastatic melanoma patients, regardless of BRAF mutation status, puts Bristol on equal footing with Merck in the indication, and positions it to take on the BRAF inhibitors.